Related Links
ARALAST NP Therapy
Choose a therapy that offers support for your patients.
Alpha-1 as Seen
on PBS
Watch the PBS show about Alpha-1.
Articles
For reprints, contact your Baxter/ARALAST NP representative at 1-866-ARALAST (272-5278).
Alpha1-antitrypsin deficiency: incidence and detection program. Campbell EJ. Respir Med. 2000;94(suppl C):S18-S21.
Alpha1-Antitrypsin deficiency: Memorandum from WHO meeting. World Health Organization. Bulletin of the World Health Organization. 1997;75:397-415.
American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900.
Biochemical efficacy and safety of a new pooled human plasma alpha1- antitrypsin, Respitin. Stoller JK, Rouhani F, Brantly M, et al. Chest. 2002;122:66-74.
Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Seersholm N, Wencker M, Banik N, et al. Eur Respir J 1997;10:2260-2263
Longitudinal follow-Up of patients with alpha1-protease inhibitor deficiency before and during therapy with IV alpha1-protease inhibitor. Wencker M, Fuhrmann B, Banik N, Konietzko N. Chest 2001;119:737-744.
Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wencker M, Banik N, Buhl R, et al. Eur Respir J. 1998;11:428-433.
Screening for alpha1-Pi deficiency in patients with lung diseases. Wencker, M. Respir Med 2000;94(suppl C):S16-S17.
Survival and FEV1 Decline in Individuals with Severe Deficiency of Alpha-1 Antitrypsin. Alpha-1 Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med. 1998;158:49-59.
Worldwide Racial and Ethnic Distribution of Alpha1-Antitrypsin Deficiency. de Serres FJ. Chest. 2002;122:1818-1829.
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Please review the Important Risk Information and the Full Prescribing Information
Please review the Important Risk Information and the Full Prescribing Information
